1,3-Benzodioxolylpentanamine

BDP
Clinical data
Other names1-(3,4-Methylenedioxyphenyl)-2-aminopentane; 3,4-Methylenedioxy-α-propylphenethylamine; MDPPEA; α-Propyl-1,3-benzodioxole-5-ethanamine; α-Propyl-3,4-methylenedioxyphenethylamine; α-Pr-MDPEA; 2-Amino-1-(3,4-methylenedioxyphenyl)pentane
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown
Identifiers
  • 1-(1,3-benzodioxol-5-yl)pentan-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC12H17NO2
Molar mass207.273 g·mol−1
3D model (JSmol)
  • CCCC(CC1=CC2=C(C=C1)OCO2)N
  • InChI=1S/C12H17NO2/c1-2-3-10(13)6-9-4-5-11-12(7-9)15-8-14-11/h4-5,7,10H,2-3,6,8,13H2,1H3
  • Key:BWUFCVGRQFOTOA-UHFFFAOYSA-N

1,3-Benzodioxolylpentanamine (BDP), also known as K or as 3,4-methylenedioxy-α-propylphenethylamine (MDPPEA), is a drug of the phenethylamine and amphetamine families. It is the parent compound of 1,3-benzodioxolyl-N-methylpentanamine (MBDP; methyl-K) and 1,3-benzodioxolyl-N-ethylpentanamine (EBDP; ethyl-K), as well as of pentylone (βk-MBDP). The drug was synthesized by Alexander Shulgin and mentioned in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved). In contrast to MBDP and EBDP however, BDP did not have its own entry in PiHKAL and is not known to have ever been tried by humans. Very little is known about BDP.